Head and Senior Consultant, Department of Endocrinology, Singapore General Hospital;Vice-President, Diabetes Singapore
Prof Jonathan Shaw
Deputy Director at Melbourne’s Baker Heart and Diabetes Institute
Dr Francis CC Chow
Consultant Endocrinologist & Honorary Associate Professor Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong
Home > Education & CME > Webinar > Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients
Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients
At the heart of the discussion on diabetes, this webinar will discuss the importance of cardiovascular risk assessment for your type 2 diabetes mellitus patients. With the new tools on assessment, we will have a heart-to-heart talk with the experts and share how the biomarker keeps the beat.
Let’s register and find out during the webinar.
Faculty
Moderator
Dr Bee Yong Mong
Head and Senior Consultant, Department of Endocrinology, Singapore General Hospital
Clinical Associate Professor, Duke-NUS Medical School
Dr. Bee Yong Mong is Head and Senior Consultant in the Department of Endocrinology, Singapore General Hospital (SGH) and Clinical Associate Professor at the Duke-NUS Medical School, Singapore. He is also the Vice President of Diabetes Singapore (DS). Dr. Bee has active research programmes around diabetes prevention, risk prediction of diabetic complications and artificial intelligence/machine learning in diabetes care. He is the Principal Investigator of the A*STAR-funded Diabetes Clinic of the Future programme, which aims to develop solutions using big data analytics, behavioural economics and digital technology to personalise care and improve outcomes among the multi-ethnic diabetes population in Singapore.
Speaker
Prof Jonathan Shaw
Deputy Director at Melbourne’s Baker Heart and Diabetes Institute
Professor Jonathan Shaw is Deputy Director at Melbourne’s Baker Heart and Diabetes Institute, where his research focuses on epidemiology and clinical research in diabetes, and he is also a consultant physician in the diabetes services. In 2014, he was included in the Thomson Reuters The World’s Most Influential Scientific Minds, which listed the 1% most highly cited scientists in the world. In 2017 and
2018, he was included in the Clarivate list of the world’s most Highly Cited Researchers. In 2020, he was
listed in the Stanford University listing of the world’s top 2% of researchers.
Speaker
Dr Francis CC Chow
Consultant Endocrinologist & Honorary Associate Professor Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong
Chairman & Managing Director, Hong Kong Diabetes Specialist Centre Hong Kong SAR
Dr Francis C.C. Chow is a Consultant Endocrinologist and Honorary Associate Professor at the Chinese University of Hong Kong. He has retired from his positions as Chief of the Service of the Department of Medicine and Therapeutics, Prince of Wales Hospital, and the Co-Director of the CUHK-PWH Diabetes and Endocrine Centre, an IDF Centre of Education, since June 2018. He is currently Chairman & Managing Director of the Hong Kong Diabetes Specialist Centre and is also President of the Hong Kong Association for the Study of Obesity.
Dr Chow has participated as a principal investigator in clinical trials for insulin aspart, biaspart, insulin degludec, insulin detemir, iDegLira, liraglutide and semaglutide. He has been the national principal investigator of more than 40 multi-national, multi-centre phase II and III clinical trials since 1998, including NAVIGATOR, CAROLINA, EXAMINE, BEGIN, BOOST, SCALE, SUSTAIN, PIONEER and SOUL. Over the years, he has published extensively, and is the leading author and co-author of over 200 publications of original research and reviews in peer-reviewed international journals. His research interests include epidemiology and treatment modalities in diabetes, obesity, thyroid disorders and pituitary disease.
Who should attend:
Cardiologists, Diabetologists, Endocrinologists, GPs and Healthcare professionals interested in the topic
Key reasons to attend:
To learn about the cardiovascular disease and heart failure risks in diabetic patients
To understand the value of NT-proBNP in clinical use
To know the clinical approach of managing patients with elevated NT-proBNP
To be aware on the guidelines on usage of NT-proBNP
To hear from APAC Endocrinologist on real world clinical implementation of NT-proBNP in T2DM patients
Agenda
h4 {
font-size:100%;
}
.col-author {
visibility:hidden;
}
@media only screen and (max-width: 600px), screen and (max-height: 480px) {
.col-author {
display:none !important;
}
}
function ShowSpeakerInformation(a,b) {
console.log(“.”+b);
$(“.”+b).toggle();
}
TIME
TOPIC
SPEAKERS
13:30 – 13:35
Welcome and Intro
Dr Bee Yong Mong
13:35 – 13:55
What and How: NT-proBNP as a tool for CVD risk assessment in T2DM
Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]
Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...
